Adaptimmune Therapeutics plc ADAP · Stock Open Adaptimmune Therapeutics plc in new tab
Adaptimmune Therapeutics plc Analysis (ADAP)
Is Adaptimmune Therapeutics plc a good investment? Adaptimmune Therapeutics plc (ADAP) is currently trading at 0.0485 USD. Market analysts have a consensus price target of 0.68 USD. This suggests a potential upside from current levels.
Earnings Schedule: Adaptimmune Therapeutics plc is expected to release its next earnings report on May 11, 2026. The market consensus estimate for Forward EPS is -0.38.
Investor FAQ
Does Adaptimmune Therapeutics plc pay a dividend?
No, it does not currently pay a dividend.
What asset class is Adaptimmune Therapeutics plc?
Adaptimmune Therapeutics plc is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be May 11, 2026. The company currently has a trailing EPS of -0.66.
Company Profile
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Community Discussion